Siga Technologies (NASDAQ:SIGA) Issues Quarterly Earnings Results

Siga Technologies (NASDAQ:SIGA) issued its earnings results on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, FiscalAI reports. Siga Technologies had a return on equity of 11.25% and a net margin of 24.61%.The company had revenue of $6.24 million during the quarter.

Here are the key takeaways from Siga Technologies’ conference call:

• SIGA expects approximately $13 million of oral TPOXX deliveries to an international customer in Q2 plus additional IV TPOXX shipments to the U.S. SNS, which should materially boost near-term product revenue versus Q1.
• The company reported a strong balance sheet with about $146 million in cash and no debt at March 31, 2026, and paid a $0.60 special cash dividend while stating pro forma cash would remain above $100 million.
• The CHMP recommended withdrawing the mpox indication in Europe (while reaffirming smallpox, cowpox and vaccinia), which could limit EU label-based use and potential demand beyond core smallpox stockpiling.
• SIGA entered an exclusive licensing and distribution agreement with Hikma for the MENA region, with SIGA as the exclusive finished-product supplier, positioning the company to access underrepresented markets (financial terms confidential).
• Pipeline progress includes a filed IND and initiated Phase I pediatric study with results expected in H2 2026, and targeting an FDA submission for a post-exposure prophylaxis (PEP) indication within the next 12 months, representing regulatory catalysts.

Siga Technologies Stock Up 1.5%

SIGA traded up $0.07 during trading on Friday, hitting $4.80. The company’s stock had a trading volume of 1,079,699 shares, compared to its average volume of 566,908. Siga Technologies has a one year low of $4.29 and a one year high of $9.62. The firm has a market cap of $344.26 million, a PE ratio of 15.48 and a beta of 0.93. The business’s 50 day simple moving average is $5.13 and its 200-day simple moving average is $6.15.

Siga Technologies Announces Dividend

The firm also recently declared a special dividend, which was paid on Thursday, April 23rd. Shareholders of record on Tuesday, April 7th were given a $0.60 dividend. The ex-dividend date was Tuesday, April 7th.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Siga Technologies from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, April 10th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SIGA. Jane Street Group LLC raised its position in Siga Technologies by 138.4% in the first quarter. Jane Street Group LLC now owns 114,147 shares of the company’s stock worth $626,000 after acquiring an additional 66,265 shares during the period. Strs Ohio bought a new stake in shares of Siga Technologies during the 1st quarter valued at $165,000. Russell Investments Group Ltd. raised its position in shares of Siga Technologies by 57.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 15,637 shares of the company’s stock valued at $102,000 after purchasing an additional 5,712 shares during the period. First Trust Advisors LP raised its position in shares of Siga Technologies by 5.5% during the 2nd quarter. First Trust Advisors LP now owns 150,913 shares of the company’s stock valued at $984,000 after purchasing an additional 7,828 shares during the period. Finally, Walleye Capital LLC bought a new stake in shares of Siga Technologies during the 2nd quarter valued at $320,000. 55.40% of the stock is currently owned by institutional investors.

Siga Technologies Company Profile

Siga Technologies, Inc (NASDAQ: SIGA) is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of medical countermeasures for public health emergencies and biological threats. The company’s flagship product, TPOXX® (tecovirimat), is the first and only antiviral approved by the U.S. Food and Drug Administration for the treatment of smallpox. Siga has entered into procurement and development contracts with U.S. government agencies, including the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense, to supply TPOXX® for the Strategic National Stockpile.

Founded in 2002, Siga has built a pipeline of therapies targeting high-consequence pathogens such as smallpox, plague and other potential biothreat agents.